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Abstract
We tested the hypothesis that therapeutic vaccination against HIV-1 can increase the frequency and suppressive function of
regulatory, CD4+ T cells (Treg), thereby masking enhancement of HIV-1-specific CD8+ T cell response. HIV-1-infected subjects
on antiretroviral therapy (N = 17) enrolled in a phase I therapeutic vaccine trial received 2 doses of autologous dendritic cells
(DC) loaded with HIV-1 peptides. The frequency of CD4+CD25hiFOXP3+ Treg in blood was determined prior to and after
vaccination in subjects and normal controls. Polyfunctional CD8+ T cell responses were determined pre- and post-vaccine
(N = 7) for 5 immune mediators after in vitro stimulation with Gag peptide, staphylococcal enterotoxin B (SEB), or medium
alone. Total vaccine response (post-vaccine–pre-vaccine) was compared in the Treg(+) and Treg-depleted (Treg-) sets. After
vaccination, 12/17 subjects showed a trend of increased Treg frequency (P = 0.06) from 0.74% to 1.2%. The increased
frequency did not correlate with CD8+ T cell vaccine response by enzyme linked immunosorbent assay for interferon c
production. Although there was no significant change in CD8+ T cell polyfunctional response after vaccination, Treg
depletion increased the polyfunctionality of the total vaccine response (P = 0.029), with a.2-fold increase in the percentage
of CD8+ T cells producing multiple immune mediators. In contrast, depletion of Treg did not enhance polyfunctional T cell
response to SEB, implying specificity of suppression to HIV-1 Gag. Therapeutic immunization with a DC-based vaccine
against HIV-1 caused a modest increase in Treg frequency and a significant increase in HIV-1-specific, Treg suppressive
function. The Treg suppressive effect masked an increase in the vaccine-induced anti-HIV-1-specific polyfunctional response.
The role of Treg should be considered in immunotherapeutic trials of HIV-1 infection.
Citation: Macatangay BJC, Szajnik ME, Whiteside TL, Riddler SA, Rinaldo CR (2010) Regulatory T Cell Suppression of Gag-Specific CD8+ T Cell Polyfunctional
Response After Therapeutic Vaccination of HIV-1-Infected Patients on ART. PLoS ONE 5(3): e9852. doi:10.1371/journal.pone.0009852
Editor: Esper Georges Kallas, University of Sao Paulo, Brazil
Received August 28, 2009; Accepted February 5, 2010; Published March 24, 2010
Copyright:  2010 Macatangay et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was funded by NIH grants: U19-AI55794, PO1-DE12321, R37-AI41870, and NIR/NCRR/GCRC grant MO1-RR-000056. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: macatangaybj@upmc.edu
Introduction
The ability of regulatory T cells (Treg) to control the immune
response to infections can have serious implications in the body’s
capability to eradicate invading pathogens. The normal physio-
logic function of Treg is to mediate peripheral tolerance, thereby
preventing autoimmunity [1], and to limit the damage caused by
inflammatory responses to infectious agents. However, Treg-
mediated suppression can also lead to the inhibition of
antimicrobial responses and in so doing, allow persistent infections.
Although the frequency and function of Treg in the peripheral
blood and lymphatic tissues of patients with HIV-1 infection have
been explored, no consistent results have emerged. It is also
uncertain whether Treg mainly protect against or contribute to
persistent HIV-1 infection and consequent disease progression. A
number of studies have shown an increase in the frequency of Treg
in HIV-1-infected individuals particularly in those with untreated
infection and in those with detectable plasma viremia. [2–4] Such
increases in Treg could potentially interfere with functions of
antiviral CD8+ T lymphocytes and thus contribute to persistent
HIV-1 infection. Furthermore, as the CD4+ T cell population
decreases in advanced disease, the absolute number of Treg has
also been shown to proportionately decline. [2] Others have
followed Treg changes over a period of 6 months, and noted a
significant Treg decrease in the untreated HIV-1-infected
population compared to those who were virally suppressed. [5]
This depletion of Treg was associated with immune activation [6],
which has been shown to be a predictor of disease progression. [7]
In this context, depletion in the number or function of Treg
appears to contribute to HIV-1 progression. However, a nested
case-control study by Cao et al. [8] showed significant expansion
of Treg and increase in T cell activation in subjects with rapidly
progressing HIV-1 infection. These conflicting results might reflect
methodologic differences in identifying human Treg, as no
universally acceptable marker has been defined for these cells.
Since the FOXP3 transcription factor is not universally correlated
with regulatory activity in humans [1], it cannot be reliably used
for human Treg identification. Additionally, cross-sectional studies
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have a limited value in comparison with longitudinal analyses of
Treg. Despite the inconsistent frequency results, functional studies
have demonstrated that Treg isolated from both peripheral blood
and lymphoid tissues of HIV-1 infected individuals show strong
suppressor activity and that they suppress HIV-1-specific effector
functions of T cells. [2,9,10] Specifically, Treg isolated from HIV-
infected patients have been shown to suppress HIV-1-specific
CD8+ T cell interferon c (IFNc) and tumor necrosis factor a
(TNFa) secretion as well as Gag-specific cytolytic activity. [11]
We have completed a phase I therapeutic vaccination trial in
which autologous dendritic cells (DC) loaded with HIV-1 peptides
representing immunodominant epitopes were delivered either
subcutaneously or intravascularly to subjects with chronic HIV-1
infection on antiretroviral therapy (ART). [12] The ultimate goal
of this approach is to elicit robust immune responses against the
virus, resulting in a control of viral replication and prevention of
disease progression. We demonstrated feasibility and safety of this
vaccine and observed a modest and transient increase in the
number of T cells producing HIV-1-peptide-specific IFNc as
detected by the enzyme linked immunosorbent (ELISPOT) assay.
We hypothesized that the observed responses were modest because
the vaccine for HIV-1 designed to increase the immune response
to the virus, had led to an increase in the frequency and
suppressive function of Treg resulting in down modulation of the
response. To test this hypothesis, we evaluated Treg frequency and
their ability to suppress HIV-1 specific polyfunctional CD8+ T cell
response using cryopreserved blood specimens from the vaccinated
patients. This is because studies have shown that an effective
immune response against HIV is characterized by the ability of
CD8+ T cells to produce multiple immune mediators: IFNc,
interleukin-2 (IL2), TNFa, macrophage inflammatory protein
1b(MIP-1b), and the cytotoxic degranulation molecule CD107a.
[13] These responses have been demonstrated in HIV-1-infected
individuals who are able to control the virus without ART and
directly correlate with CD4 counts and inversely correlate with
viremia and disease progression. [14–16]
Materials and Methods
Ethics Statement
Peripheral blood mononuclear cells (PBMC) used in this study
were obtained from the participants of the therapeutic DC vaccine
study reported by Connolly et al. [12] This study was approved by
the University of Pittsburgh Institutional Review Board. A written
informed consent was signed by all the subjects including the
consent to use the cryopreserved PBMC for further immunologic
studies.
Study Population
Eighteen HIV-1-infected, HLA A*0201 positive subjects with
suppression of plasma HIV-1 RNA (,50 copies/mL) on a stable
antiretroviral regimen were included in the study. Briefly, the
subjects received 2 doses (either subcutaneous or intravenous)
of a vaccine composed of autologous DC. The monocyte-derived
DCs were generated by culturing monocytes, obtained by
leukapheresis, with IL-4 and granulocyte-monocyte colony
stimulating factor (GM-CSF), then matured with IL-6, IL-1b,
and TNF-a, and finally loaded with synthetic peptides Gag (362–
370, VLAEAMSQV) (VV9), Pol (464–472, ILKEPVHGV) (IV9),
Env (121–129, KLTPLCVTL) (KL9), which are three highly
conserved, HIV-1, immunodominant, HLA A*0201-restricted
peptides, and an influenza A matrix protein peptide (58–66,
GILGFVFTL) (GL9). These epitope sequences were based
on HIV-1 strain HXB2 in the Los Alamos HIV Mole-
cular Immunology Database (http://www.hiv.lanl.gov/content/
immunology/index.html). It should be noted that these amino acid
Figure 1. Gating of Treg in representative subjects. Shown above is the gating used to determined the Treg frequency in a representative
normal control (A) and an HIV-1-infected subject, pre-vaccine (B). The Treg population was defined as CD3+CD4+CD25HIFOXP3+.
doi:10.1371/journal.pone.0009852.g001
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positions differ from those previously published [12] which were
based on Altfeld et. al. [17]. The two vaccine doses were given 2
weeks apart. The immune responses to the vaccine were evaluated
in an ELISPOT assay for IFNc production. PBMC obtained from
17 subjects who received both vaccine doses were used.
Polyfunctional studies were performed on PBMC from 7 subjects
with available samples.
Evaluation of CD8+ T cell Polyfunctionality
Cryopreserved PBMC from 7 subjects were obtained at baseline
and at 2 weeks after the second vaccine dose, and were thawed for
intracellular cytokine staining (ICS) and analyzed by flow cytometry
in order to measure the expression of the following immune
mediators: IFNc, TNFa, IL-2, MIP-1b, and CD107a. [18–20] Cells
were rested in media overnight at 37uC and then washed. Aliquots of
106 cells from paired pre- and post-vaccine samples were then co-
cultured with Gag peptide (VV9, 10 mL at 0.1 mg/mL), anti-CD28/
49d monoclonal antibody (mAb) (2 mL at 1 mg/mL, BD Bioscience),
anti-CD107a mAb PE-Cy5 (20 mL, BD Pharmingen), monensin
(2 mL of 5 mg/mL, Sigma), brefeldin A (2 mL of 5 mg/mL, BD
Bioscience) and PBS (14 mL) in a 96-well plate. The negative control
was medium only and the positive control was cells stimulated with
Staphylococcus enterotoxin B (SEB) (4 mL of 50 mg/mL, Sigma). Plates
were incubated at 37uC for 6 h and then at 4uC for 16 h. [19] Cells
were washed and then simultaneously stained with anti-CD3 mAb
PE-Cy7 (5 mL; BD Pharmingen), anti-CD8 mAb APC-Cy7 (5 mL;
Biolegend), and anti-CD4 mAb AF 700 (5 ml/; BD Pharmingen),
incubated in the dark for 30 minutes at room temperature (RT), and
then washed. BD FACS Lysing solution (100 ml/well) was added and
incubated for 10 minutes at RT. The plates were washed with cold
buffer, treated with BD FACS Permeabilizing Solution 2 (200 ml/
well), incubated for 10 minutes at RT, and then washed with 200 ml/
well of the cold buffer. The following mAb were then added: anti-
TNFa PB (20 mL, eBioscience), anti-MIP-1b PE (5 mL, BD
Pharmingen), anti-IL2 APC (5 mL, Biolegend), and anti-IFNc FITC
(1 mL, BD Pharmingen). The plates were incubated in the dark for
30 min, washed with 150 ml/well of cold buffer, and fixed with 1%
paraformaldehyde in PBS. Cells were analyzed using a LSR-II 12-
color flow cytometer (BD Biosciences). The total vaccine response for
each subject was obtained by subtracting pre-vaccine from post-
vaccine responses, that is, subtracting the pre-vaccine percentages of
CD8+ T cells secreting one or a combination of immune mediators
from the post-vaccine percentages. The total vaccine response
represents the vaccine-induced change in CD8+ T cell immune
mediator secretion from baseline. Polyfunctional responses of CD8+
T cells pre- and post-vaccine and the total vaccine response were
assessed using the SPICE program (Version 4.3, Mario Roederer,
Vaccine Research Center, NIAID, NIH).
Figure 2. Percentages of CD8+ T cells with poly vs monofunc-
tional responses before and after vaccination. Bars are the mean
percentages (+SE) of CD8+ T cells in paired pre- and post-vaccine
samples secreting one (monofxn) or more than one (polyfxn) immune
mediators (IFNc, TNFa, IL-2, MIP-1b, and CD107a) in response to Gag
peptide. (P =NS; N = 7)
doi:10.1371/journal.pone.0009852.g002
Figure 3. Comparison of CD45RO, FOXP3, GITR, and CTLA4 expression. The mean percentage expression in CD4+CD25HI T cells was
compared among normal control (NC; N= 10) and the HIV-1-infected subjects pre- and post-vaccine (N= 17). CD4+CD25HI expression of GITR and
CTLA4 in HIV-1-infected subjects (pre- and post-vaccine) was higher than in NC. (P,0.01)
doi:10.1371/journal.pone.0009852.g003
Treg in HIV-1 Immunotherapy
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Immunophenotyping and Treg Frequency
We obtained PBMC from stored samples of all 17 subjects at
baseline, two weeks post-vaccination (week 6), and 12 weeks post-
vaccination (week 16). Cryopreserved cells were thawed, placed in
5 different tubes (per subject), and stained with 5 ml each of anti-
CD3 mAb ECD, anti-CD4 mAb PC5, anti-CD25 mAb PE
(Beckman Coulter), and the following mAb, one in each tube: anti-
CD45RO FITC, anti-glucocorticoid-induced tumor necrosis
factor receptor (GITR) FITC (Beckman Coulter). For the other
two tubes, cells were first stained with anti-CD3, anti-CD4, and
anti-CD25 mAb, and then they were permeabilized with 300 mL
of 1% saponin for 30 minutes, washed, stained with 5 ml each of
anti-FOXP3 mAb FITC (eBioscience) and anti-cytotoxic T-
lymphocyte antigen 4 (CTLA-4) mAb PE (Beckman Coulter),
and then incubated in the dark for another 30 minutes. In the tube
containing cells stained with anti-CTLA4 PE, anti-CD25 FITC
was used. Cells were then washed and fixed with 1% paraformal-
dehyde in PBS and then analyzed using a 4-color flow cytometer
(Beckman Coulter). PBMC obtained from 10 HIV-1 negative
controls (NC) were also phenotyped for comparison. The Treg
population was identified as CD3+CD4+CD25hiFOXP3+ (Fig. 1),
and percentages of this population were determined for each time
point in every subject. The mean of five replicates of the Treg
population was used as the Treg frequency for a particular subject.
CD3+CD4+CD25hi phenotypic profiles were compared for the
expression of CD45RO, FOXP3, GITR, and CTLA4. The pre- to
post-vaccine changes in the Treg frequency were correlated with
the levels of anti-HIV-1 immune response measured in an
ELISPOT assay. A positive response in the assay was defined as
a response of.10 spots per 105 PBMC, background subtracted, to
any of the three HIV-1 peptides, 2 weeks after the second vaccine
dose. Pre-vaccine responses greater than post-vaccine responses
were considered as no response.
Evaluation of Treg Suppressive Function
Stored PBMC were obtained pre- and post-vaccine from the 7
subjects on whom polyfunctional studies were done. The
population of Treg was depleted using two different methods: in
three subjects, we removed the CD4+CD25+ Treg using a
magnetic bead separation system (AutoMACS cell separation,
Miltenyi Biotec), as per manufacturer’s instructions, while in the
other 4 subjects, we used a flow-based cell sorter (Beckman
Coulter MoFlo) to separate the CD4+CD25hi T cells. The
remaining cells were then evaluated for CD8+ T cell polyfunction-
ality using the methods described above. The polyfunctionality of
the total vaccine response (post-vaccine–pre-vaccine response)
with and without Treg depletion were then compared using
SPICE.
Statistical analysis
Two-tailed signed rank test was used to compare Treg
frequencies between the time points. Comparisons between the
immunophenotype of NC, pre-, and post-vaccine were made using
Kruskal-Wallis and Mann-Whitney U tests. Analysis of flow
cytometry data and creation of Boolean combinations of single
functional gates were done using BD Diva software. All data were
Figure 4. Treg frequency in paired pre- and post-vaccine of the 17 subjects. Percentages of CD4+CD25HIFOXP3+ T cells before (pre-vaccine)
and 2 weeks after therapeutic vaccination in each of the 17 HIV-1-infected subjects are shown. Asterisks indicate subjects who had a positive vaccine
response by ELISPOT analyses. There was a trend of increased Treg frequency post-vaccine. (P = 0.06)
doi:10.1371/journal.pone.0009852.g004
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background subtracted. Total vaccine response was obtained by
subtracting the pre-vaccine response from the post-vaccine
response. Statistical analysis of the Boolean-gated data used in
the polyfunctional responses was done using the SPICE software
that uses a permutation comparison test, based on chi-square
statistics, for comparison between pie charts.
Results
Demographics and Vaccine Response
The baseline characteristics of the subjects have been previously
described. [12] Briefly, 14/17 subjects who were included in this
study were male. The median CD4+ T cell count nadir was 259
while the median pre-vaccine CD4+ T cell count was 717 cells/
mm3. All of the subjects were on a stable antiretroviral regimen
and had an HIV RNA of,50 copies/mL. Based on our definition
of a positive immune response in IFNc production by ELISPOT,
6/17 subjects were considered responders to at least one peptide,
two of whom had a positive response to Gag peptide.
Polyfunctional response of CD8+ T cells to the vaccine using our
flow-based assay was evaluated in 7 subjects, 4 of whom were
vaccine responders via the ELISPOT assay (data not shown).
Polyfunctional responses were detected in all 7 subjects in both
pre- and post-vaccine samples using ICS (Fig. 2). There was no
significant change in the pattern of polyfunctional response before
and after the vaccine. In fact, the pre-vaccine polyfunctional
responses appeared to be more extensive than those observed after
vaccine administration, implying no vaccine response (Fig. 2). All
three non-responders by the ELISPOT assay showed IFNc
production using the ICS, and in 2/3 non-responders, we detected
post-vaccine CD8+ T cells secreting IFNc plus one other immune
mediator (data not shown).
Treg Frequencies and Immunophenotype
In order to determine whether the Treg population had any
influence on the modest responses to the vaccine, we measured
the pre- and post-vaccine Treg frequency using flow cytometry in
the 17 subjects. Treg gating of a representative HIV-1-infected
subject and NC are shown in Fig. 1. The mean frequency of Treg
in the CD3+CD4+ subset was 0.84% in the subjects pre-vaccine,
as compared to 0.78% in NC. Prior to vaccination, the Treg
subset in HIV-1-infected subjects was enriched in CTLA4 (20%
in NC vs. 73% in subjects; P,0.01) and GITR (27% in NC vs.
61%; P,0.01) relative to NC (Fig. 3). However, pre- and post-
vaccine Treg expressions of both CTLA4 and GITR in the HIV-
1 subjects were similar. Percent expression of CD4+CD25hi cells
for FOXP3 and CD45RO was similar among NC and study
subjects pre- and post-vaccine. After vaccination, 12/17 (70.6%)
subjects showed an increasing trend in the frequencies of Treg
(from 0.74% to 1.2%; P= 0.06) with the median increase of 30%
(Fig. 4). In 8/12, the Treg frequency increased by more than 50%
from the pre-vaccine value. Of the 11 who were considered
vaccine non-responders by ELISPOT assay, 7 (64%) had an
increase in the Treg frequency. There was no correlation
between changes in the pre- to post-vaccine Treg frequency
and the ELISPOT responses.
Figure 5. Polyfunctional response of CD8+ T cells pre- and post-vaccine after Treg depletion. The response patterns are color-coded by
the number of positive functions. The x-axis contains the combinations of positive immune mediators whereas the y-axis is the percentage of CD8+ T
cells secreting each combination. The pie charts show the proportion of CD8+ T cells that are polyfunctional, i.e., secreting more than 1 immune
mediator in response to stimulation with Gag peptide. There was increased polyfunctionality after the Treg were removed. Despite the apparent
increase in polyfunctionality, the permutation comparison test showed no statistical difference between the two pie charts. (P = 0.276; N = 7)
doi:10.1371/journal.pone.0009852.g005
Treg in HIV-1 Immunotherapy
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Treg Suppressive Function
To evaluate suppressive function, we measured the polyfunc-
tional responses of CD8+ T cells to Gag peptide (VV9) before and
after depletion of Treg from both pre- and post-vaccine PBMC in
7 subjects (Fig. 5). Upon removal of Treg, CD8+ T cell
polyfunctionality increased in the post-vaccine samples with a
greater number of the CD8+ T cells secreting multiple immune
mediators. Although there was an apparent increase in the
polyfunctional T cell response pattern post-vaccination, the
permutation comparison test was unable to detect a significant
difference between pre- and post-vaccine responses (P = 0.276).
We next evaluated polyfunctionality of the vaccine response
itself in both the Treg(+) and Treg(2) samples by looking at the
total vaccine response. As described earlier, the total vaccine
response is the difference of the post-vaccine from the pre-vaccine
response, and represents the vaccine-induced change in CD8+ T
cell immune mediator secretion from baseline. Figure 6 shows the
difference in polyfunctionality of the total vaccine response in the
Treg(+) and Treg(2) samples. Upon Treg depletion, the CD8+ T
cells were more likely to secrete 3–4 immune mediators, and the
difference in the pattern was significant (P = 0.029) (Fig. 6). The
average post-vaccine percentage of CD8+ T cells secreting at least
two immune mediators more than doubled after removal of Treg.
The samples containing Treg had a greater percentage of
monofunctional CD8+ T cells post-vaccine. The CD8+ T cells
expressed more CD107a and IFNc (in 10/31 combinations of
immune mediators) in response to Gag peptide as compared to the
other mediators. Figure 7 shows that in all of 7 subjects in whom
functional assays were done, there was an increase in the
proportion of polyfunctional CD8+ T cells after Treg depletion.
Since we used two methods for Treg depletion, we asked
whether polyfunctional responses of CD8+ T cells were influenced
by the method used. Samples obtained from either method
showed a trend towards more polyfunctionality with the removal
of Treg despite the difference in the technique (P = 0.100 when
using magnetic beads and P=0.143 when using a cell sorter, data
not shown).
We then determined whether the Treg-mediated inhibition of
polyfunctional responses was specific to the Gag peptide by
examining CD8+ T cell immune responses to the positive control,
SEB, since such superantigens have also been shown to induce
regulatory T cells in vivo. [21] Not only did the CD8+ T cells
secrete higher levels of the immune mediators, they also showed
significant polyfunctional response to SEB. (Fig. 8) However, Treg
depletion did not result in any significant change in the
polyfunctionality of the cells (P = 0.762), implying specificity of
the Treg suppressive function to the Gag peptide.
Discussion
The goal of therapeutic vaccinations in HIV-1 infection is to
provide enough antigenic stimulation so that the subject can
mount an immune response in order to effectively control viral
replication without the presence of an antiretroviral regimen.
Recent studies of HIV-1-infected individuals with natural immune
control have shown that an effective immune response is
characterized by the presence of a polyfunctional CD8+ T cell
response to the virus. [13,14,16,20] Since the control of HIV-1 has
been shown to be more dependent on the quality and specificity of
the CD8+ T cell response rather than the quantity of the response
Figure 6. Polyfunctionality of the total vaccine response with (Treg+) and without Treg (Treg2). The total vaccine response was
obtained by subtracting the pre-vaccine response from the post-vaccine response and represents the vaccine-induced change in CD8+ T cell
secretion of immune mediators from baseline. Analysis by permutation comparison showed a significant increase in polyfunctional response to Gag
peptide in the samples depleted of Treg. (P = 0.029; N = 7)
doi:10.1371/journal.pone.0009852.g006
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alone, [15] we evaluated CD8+ T cell polyfunctional response in a
previously completed DC-HIV-1 peptide vaccine trial. [12]
Interestingly, the increased monofunctional response after vacci-
nation correlated with the modest IFNc response detected using
the ELISPOT assay. However, although assessing single cell IFNc
production showed that there were transient and modest responses
to the vaccine peptides, permutation comparison analysis showed
no significant difference in the CD8+ T cell polyfunctional
response post-vaccine. In fact, it appeared that the CD8+ T cell
response to Gag peptide was more polyfunctional before the
vaccine was given.
The minimal immunologic response to this DC-peptide vaccine
could be due to its low immunogenicity. We examined an
alternative hypothesis that Treg activity affected immunologic
response in the trial. Depletion of Treg in the cord blood of HIV-
1-exposed-uninfected neonates resulted in the augmentation of
CD4+ and CD8+ T cell HIV-1-specific immune responses. [22]
Also, Treg isolated from HIV-1-infected patients have been shown
to suppress cytokine secretion. [2] Because of the major role that
Treg, especially the antigen-specific Treg induced in the
periphery, play in the immune response to chronic infections, it
was important for us to delineate the effects of Treg in this
particular study. The objective was to assess whether Treg activity
should be a co-factor in the evaluation of immune-based
therapeutic trials in HIV-1.
In our study, there was a trend of increased Treg frequency
observed in a majority of subjects after DC-HIV peptide
vaccination, with a modest median increase of 30% in the 12
subjects. Sixty four percent of vaccine non-responders by
ELISPOT assay had increases in Treg frequency compared to
83% of ELISPOT assay responders. As Treg can accumulate in
the lymphoid tissues, [2,10] the modest increase in Treg frequency
in peripheral blood as well as the lack of correlation between Treg
frequency and vaccine response detected by ELISPOT assay could
be due to migration of the expanded Treg population to the lymph
nodes where T cells are being activated by the vaccine.
Interestingly, the CD8+ T cell polyfunctional response appeared
greater prior to the vaccine, suggesting that the increase in Treg
frequency and Treg activity, could have affected the ability of
CD8+ T cells to secrete cytokines. It is also important to note that
when we checked the Treg frequencies 3 months after the vaccine
was given, the levels decreased to baseline or lower than baseline
in 14/14 subjects evaluated (data not shown) suggesting that the
increased frequencies were vaccine related.
More important than the Treg frequency is the suppressive
function, which we have shown to have an effect on the vaccine
response, as evinced by the increased polyfunctionality of the CD8+
T cell response to Gag peptide after Treg depletion. Since the
subjects have all been virally suppressed on a stable ART regimen,
there is not enough antigenic stimulation, which is believed to be
necessary for continuous anti-HIV-1 effector function. [23,24]
Upon receipt of the DC vaccine, it is likely that the Treg population
was initially activated and expanded, as has been shown in mouse
models. [25] Indeed, in the study by O’Gorman et al. [25], antigen-
specific memory CD4+ T cells only acquire responsiveness after
repeated antigenic stimulation. In our study, the high expression
levels of the IL-2 receptor a chain, CD25, on Treg could have
allowed them to sequester increased levels of IL-2 produced by the
T cells upon antigen recognition. Thus, although our DC vaccine
was able to elicit an immune response after the second dose, the
increased expansion of Treg after the first dose might have
significantly limited the total CD8+ T cell immune activity, leading
to the modest and transient response.
The specific mechanism by which the Treg exerted suppression
of polyfunctional responses of CD8+ T cells remains to be
determined. However, it should be noted that there was no change
in the expression of CTLA4 and GITR expression in Treg post-
vaccine, suggesting that there could have been other mechanisms of
suppression that were increased after vaccine administration leading
to the increased suppressive function. Antigen-specific induced Treg
such as type 1 regulatory T cells (Tr1) mediate suppression by IL10
secretion, which we were not able to test. Indeed, Lopez et al., [26]
Figure 7. Proportion of monofunctional (monofxn) and poly-
functional (polyfxn) CD8+ T cells in 7 HIV-1 subjects. The
polyfunctional vaccine response to Gag peptide in each of the 7 HIV-1-
infected subjects is shown before [Treg(+)] and after [Treg(2)] Treg
depletion.
doi:10.1371/journal.pone.0009852.g007
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point to evidence indicating that the pre-treatment with immu-
noinhibitory drugs improves immune responses of cancer patients to
DC therapy mainly because these drugs eliminate the Treg
population. As the removal of the entire Treg population will also
lead to autoimmunity [1], it is important to initially determine
which specific Treg mechanism is responsible for immune
suppression, and then, define the Treg subsets mediating suppres-
sion. In the context of enhancing CD8+ T cell responses against
HIV-1, the goal would be inhibiting Treg suppression without
causing a significant manifestation of autoimmunity.
Since polyfunctional T cell responses have been associated with
better immunologic control of HIV-1, as shown in elite controllers,
[15,16] Treg appear to play a significant role in inhibiting effective
immune responses to the virus in untreated patients. However, this
inhibition may be beneficial for the host since persistent immune
response will lead to persistent immune activation, which has been
shown as a predictor of HIV-1 disease progression. [8] Moreover,
activated T cells will also be easily targeted by the virus, thus
contributing to progressive infection. Indeed, lower numbers of
Treg have been associated with higher levels of immune activation
in HIV-1 infection. [6,27] Treg therefore seem to be maintaining a
balance between persistent infection and decreased immune
activation. As the CD4+ T cell population becomes depleted later
in the disease, untreated patients would experience both increased
immunosuppression and immune activation due to the eventual
Treg depletion. Although Treg may not be exerting a considerable
effect in virally suppressed patients on ART, an increase in the
immune response to the virus, such as after administration of a
therapeutic vaccine, may tilt this delicate balance held in check by
Treg towards a proinflammatory T cell response. This will lead the
Treg to counteract by increasing their frequency and suppressive
effects thus preventing any resulting immune activation.
We believe that this is the first study to assess Treg activity in
HIV-1 therapeutic vaccines. Although we were able to evaluate
Treg frequencies in the 17 subjects who received the vaccine, we
were only able to evaluate polyfunctional response in 7 subjects. It
is important to note, however, that in all the 7 subjects, increased
polyfunctionality was observed after Treg depletion implying that
the DC vaccine did indeed increase polyfunctional CD8+ T cell
activity but was masked by Treg expansion and increased
suppressive function. Further research should be conducted to
investigate the role of Treg in other immunotherapeutic trials for
HIV-1. The information from these studies can guide investigators
in developing better strategies to enhance HIV-1 immune control.
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